Expert Perspectives on Advances in the Management of Major Depressive Disorder

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review trends in the prevalence of major depressive disorder (MDD) in the US, and the impact of the COVID-19 pandemic on MDD trends.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, discuss the connection between depression and other health conditions, as well as the economic impact of major depressive disorder [MDD].

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh share their approach to treatment selection for patients with MDD.

Sagar V. Parikh, MD, FRCPC, leads a discussion on patient engagement and shared decision-making in treatment selection in MDD.

Gregory Mattingly, MD, provides an overview of currently available treatment options for MDD.

Sagar V. Parikh, MD, FRCPC, reviews factors that lead to the use of antidepressants in the treatment of MDD.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the limitations and challenges of traditional treatments for MDD, such as length of treatment and adverse events.

Experts in psychiatry discuss unmet needs in the treatment of major depressive disorder and how new agents are aiming to fulfill these needs.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review newly approved additions to the major depressive disorder treatment landscape, including esketamine, brexanolone, AXS-05 (dextromethorphan/bupropion).

Use of Zuranolone for Treatment of MDD

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V Parikh, MD, FRCPC, discuss clinical data on zuranolone from the WATERFALL, CORAL, and SHORELINE studies for the treatment of major depressive disorder.

Experts in psychiatry provide insight into treating episodic vs chronic major depressive disorder and factors they consider when approaching treatment selection.

Drs Andrew J Cutler, Gregory Mattingly, and Sagar V Parikh provide advice to clinicians on monitoring treatment in major depressive disorder.

Experts in psychiatry review factors to consider when deciding to switch or augment treatment in major depressive disorder [MDD].

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh discuss the treatment of MDD in female patients who are pregnant or plan to become pregnant.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, share their approach to treatment-resistant depression.

Experts in psychiatry review emerging mechanisms of action in the treatment landscape of MDD.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the need to improve awareness around depressive disorders and break the stigma of mental health treatment.